November 02, 2026 - Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals, Inc. in connection with its completed merger with Indivior Pharmaceuticals, Inc. The transaction closed on November 2, 2026, creating Supernus, Inc., a diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system diseases.
The combined company will operate as Supernus, Inc. and is expected to begin trading on the Nasdaq Global Market under the ticker symbol "SUPN" on November 3, 2026. The combination brings together an 11-product commercial portfolio spanning opioid use disorder, psychiatry and neurology.
"Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions," said Jack Khattar, President and CEO of Supernus, Inc. "As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders."
The Saul Ewing team was led by Mark Gruhin, with assistance from Julia Taylor, George Naya, David Shapiro, Kate Winslow, Lisa Koblin, Mike Finio, Joel Plainfield, Ubong Udoeyo, Jhonell Campbell, Hannah Lee, and Anthony Essick (pending bar admission). Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals, with Wells Fargo also advising. Morgan Lewis UK advised Supernus Pharmaceuticals on certain Canadian and European Union matters.
Read Supernus' press release here.
About Saul Ewing LLP
Saul Ewing is a full-service, national law firm with more than 450 attorneys and a team of top-notch business professionals, all working together to deliver practical, proactive advice and excellent client service. Our diversity of thought, focus on innovation, cross-serving practices, and culture of coaching create a collegial and supportive environment that inspires us to deliver inspired solutions. This is The Saul Approach.
